

Claudio Maria Mastroianni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3011138/publications.pdf>

Version: 2024-02-01

344
papers

8,605
citations

57758

44
h-index

85541

71
g-index

351
all docs

351
docs citations

351
times ranked

13520
citing authors

#	ARTICLE	IF	CITATIONS
1	Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3465.	4.0	203
2	Personalized profiles of antioxidant signaling pathway in patients with tuberculosis. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 405-412.	3.1	3
3	SARS-CoV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications. <i>Clinical Transplantation</i> , 2022, 36, e14495.	1.6	40
4	Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115586.	1.8	3
5	Covid-19 sequelae in working age patients: A systematic review. <i>Journal of Medical Virology</i> , 2022, 94, 858-868.	5.0	26
6	PaO ₂ /FiO ₂ ratio forecasts COVID-19 patients' outcome regardless of age: a cross-sectional, monocentric study. <i>Internal and Emergency Medicine</i> , 2022, 17, 665-673.	2.0	11
7	Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 257-266.	3.4	18
8	Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732110657.	1.0	4
9	The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 803.	4.1	8
10	Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 347.	2.4	4
11	Epidemiology of SARS-CoV-2 Infection in Italy Using Real-World Data: Methodology and Cohort Description of the Second Phase of Web-Based EPICoVID19 Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1274.	2.6	4
12	Distribution of Interferon Lambda 4 Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19. <i>Microorganisms</i> , 2022, 10, 363.	3.6	4
13	HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 239.	4.4	24
14	High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Acinetobacter baumannii</i> . <i>Antibiotics</i> , 2022, 11, 225.	3.7	8
15	Analysis of serum microRNAs and rs2910164 GC single-nucleotide polymorphism of miRNA-146a in COVID-19 patients. <i>Journal of Immunoassay and Immunochemistry</i> , 2022, 43, 347-364.	1.1	7
16	Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19. <i>Cells</i> , 2022, 11, 788.	4.1	10
17	Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 871592.	4.8	3
18	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. <i>Scientific Reports</i> , 2022, 12, 5736.	3.3	6

#	ARTICLE	IF	CITATIONS
19	Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. <i>Diagnostics</i> , 2022, 12, 76.	2.6	9
20	Anti-IFN- γ neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. <i>European Journal of Immunology</i> , 2022, 52, 1120-1128.	2.9	29
21	Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature.. <i>New Microbiologica</i> , 2022, 45, 62-72.	0.1	3
22	Prognostic Value of 12-Leads Electrocardiogram at Emergency Department in Hospitalized Patients with Coronavirus Disease-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 2537.	2.4	4
23	Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry. <i>Journal of Chemotherapy</i> , 2022, 34, 524-533.	1.5	3
24	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2022, 41, 2755-2763.	2.2	6
25	Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. <i>Biomedicines</i> , 2022, 10, 1548.	3.2	2
26	COVID-19 Severity and Androgen Receptor Polymorphism. <i>Biology</i> , 2022, 11, 974.	2.8	1
27	Post-Traumatic Stress Disorder Trajectories the Year after COVID-19 Hospitalization. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8452.	2.6	10
28	qSOFA as a new community-acquired pneumonia severity score in the emergency setting. <i>Emergency Medicine Journal</i> , 2021, 38, 906-912.	1.0	3
29	Is Albumin Predictor of Mortality in COVID-19?. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 139-142.	5.4	136
30	Targeting the NO-GMP-PDE5 pathway in COVID-19 infection. The DEDALO project. <i>Andrology</i> , 2021, 9, 33-38.	3.5	47
31	Major reduction of NKT cells in patients with severe COVID-19 pneumonia. <i>Clinical Immunology</i> , 2021, 222, 108630.	3.2	39
32	Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial. <i>Journal of Medical Virology</i> , 2021, 93, 2210-2220.	5.0	22
33	Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110101.	3.2	24
34	Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection. <i>Chemotherapy</i> , 2021, 66, 24-32.	1.6	22
35	Beyond Bone: Infectious Diseases and Immunity in Parathyroid Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2021, , 17-32.	1.6	3
36	Molecular Identification of New Cases of Human Dirofilariasis (<i>Dirofilaria repens</i>) in Italy. <i>Pathogens</i> , 2021, 10, 251.	2.8	14

#	ARTICLE	IF	CITATIONS
37	Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic. <i>Internal and Emergency Medicine</i> , 2021, 16, 541-543.	2.0	7
38	Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. <i>Frontiers in Immunology</i> , 2021, 12, 627548.	4.8	149
39	Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized Male COVID-19 Patients. <i>Diagnostics</i> , 2021, 11, 581.	2.6	9
40	Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge. <i>Journal of General Internal Medicine</i> , 2021, 36, 1702-1707.	2.6	98
41	Does Lung Ultrasound Have a Role in the Clinical Management of Pregnant Women with SARS COV2 Infection?. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2762.	2.6	8
42	Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Acinetobacter baumannii</i> : A Retrospective Case-Control Study. <i>Antibiotics</i> , 2021, 10, 271.	3.7	13
43	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	6.0	37
44	Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19). <i>Virus Research</i> , 2021, 295, 198283.	2.2	26
45	Alteration of type I interferon response is associated with subclinical atherosclerosis in virologically suppressed HIV-1 infected male patients. <i>Journal of Medical Virology</i> , 2021, 93, 4930-4938.	5.0	5
46	Low-Grade Endotoxemia and Thrombosis in COVID-19. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00348.	2.5	32
47	Early antibiotic treatment in emergency department: the critical balance. <i>Internal and Emergency Medicine</i> , 2021, 16, 1743-1745.	2.0	0
48	Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy. <i>Radiologia Medica</i> , 2021, 126, 1170-1180.	7.7	22
49	Efficacy and durability of two vs three drug integrase inhibitor based regimens in virologically suppressed HIV-1 infected patients: Data from real life ODOACRE cohort. <i>HIV Medicine</i> , 2021, 22, 843-853.	2.2	18
50	Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19. <i>Frontiers in Immunology</i> , 2021, 12, 708149.	4.8	35
51	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. <i>Internal and Emergency Medicine</i> , 2021, 16, 1231-1237.	2.0	20
52	Antiretroviral Therapy Dampens Mucosal CD4+ T Lamina Propria Lymphocytes Immune Activation in Long-Term Treated People Living with HIV-1. <i>Microorganisms</i> , 2021, 9, 1624.	3.6	1
53	Clinical Characteristics and Outcome of Patients with Suspected COVID-19 in Emergency Department (RESILIENCY Study II). <i>Diagnostics</i> , 2021, 11, 1368.	2.6	3
54	Oxygen Sparing Effect of Bacteriotherapy in COVID-19. <i>Nutrients</i> , 2021, 13, 2898.	4.1	9

#	ARTICLE	IF	CITATIONS
55	Prevalence and clinical significance of relative bradycardia at hospital admission in patients with coronavirus disease 2019 (COVID-19). <i>Clinical Microbiology and Infection</i> , 2021, 27, 1185-1187.	6.0	13
56	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 3784.	2.4	12
57	Cardiac involvement in consecutive unselected hospitalized COVID-19 population: In-hospital evaluation and one-year follow-up. <i>International Journal of Cardiology</i> , 2021, 339, 235-242.	1.7	28
58	Role of Serum E-Selectin as a Biomarker of Infection Severity in Coronavirus Disease 2019. <i>Journal of Clinical Medicine</i> , 2021, 10, 4018.	2.4	11
59	The Synergistic Effect of Time of Exposure, Distance and No Use of Personal Protective Equipment in the Determination of SARS-CoV-2 Infection: Results of a Contact Tracing Follow-Up Study in Healthcare Workers. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9456.	2.6	3
60	An observed association between conjunctivitis and severity of COVID-19. <i>Journal of Infection</i> , 2021, 83, 381-412.	3.3	8
61	Depressive Symptoms among Individuals Hospitalized with COVID-19: Three-Month Follow-Up. <i>Brain Sciences</i> , 2021, 11, 1175.	2.3	9
62	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0257376.	2.5	6
63	Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 105, 115539.	1.8	0
64	CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia. <i>Infezioni in Medicina</i> , 2021, 29, 408-415.	1.1	4
65	Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report. <i>Thrombosis and Haemostasis</i> , 2021, 121, 102-105.	3.4	36
66	Overview of current global CNS morbidity in HIV infection. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118039.	0.6	0
67	Challenges in the Microbiological Diagnosis of Implant-Associated Infections: A Summary of the Current Knowledge. <i>Frontiers in Microbiology</i> , 2021, 12, 750460.	3.5	18
68	Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4286-4301.	3.5	9
69	SARS-CoV-2 Among Migrants Recently Arrived in Europe From Low- and Middle-Income Countries: Containment Strategies and Special Features of Management in Reception Centers. <i>Frontiers in Public Health</i> , 2021, 9, 735601.	2.7	2
70	Clinical Effects of Oral Bacteriotherapy on Anal HPV Infection and Related Dysplasia in HIV-Positive MSM: Results from the "HPV in HIV" Trial. <i>Biomedicines</i> , 2021, 9, 1738.	3.2	2
71	Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients. <i>Frontiers in Nutrition</i> , 2021, 8, 756177.	3.7	6
72	Chest computed tomography score, cycle threshold values and secondary infection in predicting COVID-19 mortality. <i>New Microbiologica</i> , 2021, 44, 145-154.	0.1	2

#	ARTICLE	IF	CITATIONS
73	282â€fFollow-up of hospitalized COVID-19 survivors: assessment of short- and long-term cardiovascular sequelae after SARS-CoV-2 infection. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
74	Physical Activity and HIV: Effects on Fitness Status, Metabolism, Inflammation and Immune-Activation. <i>AIDS and Behavior</i> , 2020, 24, 1042-1050.	2.7	9
75	Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. <i>International Journal of Infectious Diseases</i> , 2020, 92, 62-68.	3.3	13
76	Interplay between male testosterone levels and the risk for subsequent invasive respiratory assistance among COVID-19 patients at hospital admission. <i>Endocrine</i> , 2020, 70, 206-210.	2.3	43
77	Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 292-296.	2.2	41
78	Xerostomia, gustatory and olfactory dysfunctions in patients with COVID-19. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2020, 41, 102721.	1.3	61
79	Retinal involvement and ocular findings in COVID-19 pneumonia patients. <i>Scientific Reports</i> , 2020, 10, 17419.	3.3	65
80	High abundance of genus <i>Prevotella</i> is associated with dysregulation of IFN-I and T cell response in HIV-1-infected patients. <i>Aids</i> , 2020, 34, 1467-1473.	2.2	14
81	False-negative RT-PCR in SARS-CoV-2 disease: experience from an Italian COVID-19 unit. <i>ERJ Open Research</i> , 2020, 6, 00324-2020.	2.6	34
82	The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. <i>Journal of Neuroimmunology</i> , 2020, 346, 577323.	2.3	21
83	Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial. <i>Metabolites</i> , 2020, 10, 274.	2.9	7
84	Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 389.	2.6	152
85	Missed Opportunities of Flu Vaccination in Italian Target Categories: Insights from the Online EPICOVID 19 Survey. <i>Vaccines</i> , 2020, 8, 669.	4.4	8
86	Comparison Between Hospitalized Patients Affected or Not Affected by Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 72, e1158-e1159.	5.8	7
87	Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882096901.	3.2	11
88	Antimicrobial Essential Oil Formulation: Chitosan Coated Nanoemulsions for Nose to Brain Delivery. <i>Pharmaceutics</i> , 2020, 12, 678.	4.5	32
89	Probiotics and COVID-19. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 721-722.	8.1	32
90	Nox2 activation in Covid-19. <i>Redox Biology</i> , 2020, 36, 101655.	9.0	114

#	ARTICLE	IF	CITATIONS
91	Procalcitonin in the Assessment of Ventilator Associated Pneumonia: A Systematic Review. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1323, 103-114.	1.6	14
92	Heart, COVID-19, and echocardiography. <i>Echocardiography</i> , 2020, 37, 1454-1464.	0.9	33
93	Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I). <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108454.	2.8	32
94	The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICoVID19 Web-Based Survey. <i>Vaccines</i> , 2020, 8, 471.	4.4	68
95	Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection. <i>Medicine (United States)</i> , 2020, 99, e21803.	1.0	18
96	Anosmia and Ageusia as Predictive Signs of COVID-19 in Healthcare Workers in Italy: A Prospective Case-Control Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2870.	2.4	27
97	Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 428-434.	0.9	11
98	Is previous influenza-like illness a potential Trojan horse for COVID-19?. <i>Critical Care</i> , 2020, 24, 503.	5.8	10
99	Efficacy of Daptomycin-Containing Regimen for Treatment of Staphylococcal or Enterococcal Vertebral Osteomyelitis: A Prospective Clinical Experience. <i>Antibiotics</i> , 2020, 9, 889.	3.7	3
100	Usefulness of bronchoalveolar lavage in suspect COVID-19 repeatedly negative swab test and interstitial lung disease. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 67-69.	2.2	9
101	Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients. <i>Biology of Sex Differences</i> , 2020, 11, 23.	4.1	11
102	Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients. <i>Journal of Clinical Virology</i> , 2020, 128, 104450.	3.1	10
103	The need of health policy perspective to protect Healthcare Workers during COVID-19 pandemic. A GRADE rapid review on the N95 respirators effectiveness. <i>PLoS ONE</i> , 2020, 15, e0234025.	2.5	45
104	Is teicoplanin a complementary treatment option for COVID-19? The question remains. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106029.	2.5	41
105	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. <i>Circulation Research</i> , 2020, 127, 400-401.	4.5	60
106	Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. <i>Nutrients</i> , 2020, 12, 1718.	4.1	155
107	Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	2.2	3
108	Antibacterial Effectiveness of Fecal Water and In Vitro Activity of a Multi-Strain Probiotic Formulation against Multi-Drug Resistant Microorganisms. <i>Microorganisms</i> , 2020, 8, 332.	3.6	2

#	ARTICLE	IF	CITATIONS
109	Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e214-e218.	2.5	25
110	Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. <i>European Radiology</i> , 2020, 30, 6808-6817.	4.5	530
111	Real world outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 485-492.	4.4	4
112	JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis. <i>Virology Journal</i> , 2020, 17, 23.	3.4	20
113	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. <i>Antibiotics</i> , 2020, 9, 71.	3.7	68
114	Persistent Systemic Microbial Translocation, Inflammation, and Intestinal Damage During <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz507.	0.9	17
115	A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 211-213.e4.	2.9	275
116	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels <i>in vivo</i> , hinder HBsAg secretion <i>in vitro</i> and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. <i>Emerging Microbes and Infections</i> , 2020, 9, 928-939.	6.5	5
117	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.9	49
118	Face Mask Use in the Community for Reducing the Spread of COVID-19: A Systematic Review. <i>Frontiers in Medicine</i> , 2020, 7, 594269.	2.6	42
119	Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. <i>Frontiers in Nutrition</i> , 2020, 7, 613928.	3.7	55
120	Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). <i>Cardiovascular Diabetology</i> , 2020, 19, 164.	6.8	90
121	Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOVID19 Web-Based Survey. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e21866.	2.6	63
122	Monocyte absolute count as a preliminary tool to distinguish between SARS-CoV-2 and influenza A/B infections in patients requiring hospitalization. <i>Infezioni in Medicina</i> , 2020, 28, 534-538.	1.1	2
123	Diagnostic Issues of Asymptomatic Neurosyphilis in HIV-Positive Patients: A Retrospective Study. <i>Brain Sciences</i> , 2019, 9, 278.	2.3	13
124	SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels <i>in vivo</i> , hamper HBsAg secretion <i>in vitro</i> and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection. <i>Journal of Hepatology</i> , 2019, 70, e713-e714.	3.7	0
125	HepaDisk – A new quality of life questionnaire for HCV patients. <i>Digestive and Liver Disease</i> , 2019, 51, 1008-1015.	0.9	3
126	Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients. <i>Scientific Reports</i> , 2019, 9, 311.	3.3	12

#	ARTICLE	IF	CITATIONS
127	BioTimer assay as complementary method to vortex-sonication-vortex technique for the microbiological diagnosis of implant associated infections. <i>Scientific Reports</i> , 2019, 9, 7534.	3.3	6
128	Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience. <i>Digestive and Liver Disease</i> , 2019, 51, e53-e54.	0.9	0
129	Impact of the 2017 measles outbreak on the emergency care system of a large tertiary-care teaching hospital in Italy: a retrospective analysis. <i>European Journal of Public Health</i> , 2019, 29, 966-971.	0.3	8
130	Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. <i>Annals of Hepatology</i> , 2019, 18, 434-438.	1.5	8
131	Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection. <i>Digestive and Liver Disease</i> , 2019, 51, e60.	0.9	0
132	In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant <i>Acinetobacter Baumannii</i> . <i>Molecules</i> , 2019, 24, 886.	3.8	12
133	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 846-855.	2.0	9
134	Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. <i>Journal of Infection</i> , 2019, 79, 15-23.	3.3	16
135	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. <i>Virus Genes</i> , 2019, 55, 290-297.	1.6	0
136	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e17-e21.	2.1	2
137	Increased IL-17 and/or IFN- γ producing T-cell subsets in gut mucosa of long-term-treated HIV-1-infected women. <i>Aids</i> , 2019, 33, 627-636.	2.2	7
138	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 895-902.	1.8	9
139	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 408-415.	2.5	120
140	Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy356.	0.9	54
141	Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25/CD134 in response to new antigens of <i>Mycobacterium tuberculosis</i> . <i>Medical Microbiology and Immunology</i> , 2019, 208, 171-183.	4.8	6
142	Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry. <i>Journal of Chemotherapy</i> , 2019, 31, 9-14.	1.5	14
143	Myeloid and lymphoid activation markers in AIDS and non-AIDS presenters. <i>Immunobiology</i> , 2019, 224, 231-241.	1.9	8
144	Aseptic meningitis induced by intravenous immunoglobulins in a child with acute Epstein-Barr virus infection and thrombocytopenia. <i>Infezioni in Medicina</i> , 2019, 27, 194-197.	1.1	4

#	ARTICLE	IF	CITATIONS
145	<i>In vitro</i> effect of antiretroviral drugs on cultured primary astrocytes: analysis of neurotoxicity and matrix metalloproteinase inhibition. <i>Journal of Neurochemistry</i> , 2018, 144, 271-284.	3.9	24
146	Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant <i>Enterobacteriaceae</i>: A Single-Center, Observational Study. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	19
147	Genetic divergence of HIV-1 B subtype in Italy over the years 2003â€“2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018, 8, 15739.	3.3	2
148	Persistent high plasma levels of sCD163 and sCD14 in adult patients with measles virus infection. <i>PLoS ONE</i> , 2018, 13, e0198174.	2.5	8
149	Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases. <i>Scientific Reports</i> , 2018, 8, 7881.	3.3	8
150	JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	9
151	Intracranial tuberculous mass lesions treated with thalidomide in an immunocompetent child from a low tuberculosis endemic country. <i>Medicine (United States)</i> , 2018, 97, e11186.	1.0	9
152	Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection. <i>Journal of Hepatology</i> , 2018, 68, S492-S493.	3.7	0
153	Systemic adipokines, hepatokines and interleukin-6 in HCV-monoinfected and HCV/HIV coinfecting patients treated with direct antiviral agents (DAAs). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, e45-e48.	1.5	1
154	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. <i>Journal of Clinical Virology</i> , 2018, 104, 61-64.	3.1	19
155	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018, 10, 363.	3.3	4
156	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir Â± ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0192627.	2.5	6
157	Detection of biofilm-associated implant pathogens in cardiac device infections: High sensitivity of sonication fluid culture even in the presence of antimicrobials. <i>Journal of Global Infectious Diseases</i> , 2018, 10, 74.	0.5	5
158	Prise en charge de lâ€™infection par le virus de lâ€™hÃ©patite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 115-120.	0.0	0
159	Multiclass <sc>HCV</sc> resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	3.9	84
160	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 525-530.	1.6	15
161	Case report: human papilloma virus type 120-related papillomatosis mimicking laryngeal carcinoma. <i>Infection</i> , 2017, 45, 709-713.	4.7	1
162	Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-Î³)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 644-655.	1.5	22

#	ARTICLE	IF	CITATIONS
163	In vitro evaluation of different antimicrobial combinations against carbapenemase-producing <i>Klebsiella pneumoniae</i> : the activity of the double-carbapenem regimen is related to meropenem MIC value. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1981-1984.	3.0	30
164	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017, 23, 267.e1-267.e4.	6.0	11
165	HCV and diabetes: towards a "Sustained" glycaemic improvement after treatment with DAAs? Authors' reply. <i>Clinical Microbiology and Infection</i> , 2017, 23, 344.	6.0	0
166	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2837-2845.	3.0	15
167	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2827-2837.	3.9	18
168	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
169	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 465-471.	2.1	4
170	Immunological diagnosis as an adjunctive tool for an early diagnosis of tuberculous meningitis of an immune competent child in a low tuberculosis endemic country: a case report. <i>BMC Research Notes</i> , 2017, 10, 123.	1.4	4
171	Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant <i>Klebsiella pneumoniae</i> (CR-Kp). <i>Journal of Infection</i> , 2017, 74, 103-106.	3.3	38
172	Diplopia as isolated presentation of varicella zoster central nervous system reactivation. <i>Journal of NeuroVirology</i> , 2017, 23, 621-624.	2.1	1
173	Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. <i>PLoS ONE</i> , 2017, 12, e0179400.	2.5	40
174	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017, 12, e0187393.	2.5	11
175	Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant <i>Acinetobacter baumannii</i> causing ventilator-associated pneumonia. <i>New Microbiologica</i> , 2017, 40, 205-207.	0.1	8
176	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1018-1028.	0.8	8
177	The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. <i>Clinical Rheumatology</i> , 2016, 35, 1383-1388.	2.2	7
178	Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors. <i>International Journal of Molecular Sciences</i> , 2016, 17, 455.	4.1	30
179	Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients. <i>PLoS ONE</i> , 2016, 11, e0149601.	2.5	14
180	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 263-271.	2.1	39

#	ARTICLE	IF	CITATIONS
181	Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing. <i>Medicine (United States)</i> , 2016, 95, e2243.	1.0	13
182	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw846.	5.8	8
183	Herpes virus reactivation after initiation of interferon-free antiviral agents in HIV+HCV-coinfected subjects: a new immune restoration disease?. <i>Antiviral Therapy</i> , 2016, 21, 739-742.	1.0	5
184	Immunosuppression-driven HBV reactivation in patients with resolved HBV infection correlates with a relevant risk of death and with evolution towards active chronic infection. <i>Digestive and Liver Disease</i> , 2016, 48, e18-e19.	0.9	0
185	Nursing home residence is associated with spread of <i>Clostridium difficile</i> ribotype O27 in central Italy. <i>Journal of Hospital Infection</i> , 2016, 94, 201-203.	2.9	4
186	Pregnancy outcomes and cytomegalovirus DNAemia in HIV-infected pregnant women with CMV. <i>Clinical Microbiology and Infection</i> , 2016, 22, 818-820.	6.0	2
187	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. <i>Journal of Clinical Virology</i> , 2016, 82, 94-100.	3.1	35
188	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.	3.0	13
189	Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. <i>Clinical Microbiology and Infection</i> , 2016, 22, 462.e1-462.e3.	6.0	77
190	Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAZANAVIR & GLUCOSE metabolism (ATAGLU) study. <i>International Journal of STD and AIDS</i> , 2016, 27, 638-643.	1.1	5
191	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 288.e1-288.e8.	6.0	33
192	Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing <i>Klebsiella pneumoniae</i> . <i>Clinical Microbiology and Infection</i> , 2016, 22, 147-153.	6.0	47
193	Treatment of latent tuberculosis infection induces changes in multifunctional <i>Mycobacterium tuberculosis</i> -specific CD4+ T cells. <i>Medical Microbiology and Immunology</i> , 2016, 205, 37-45.	4.8	5
194	Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation. <i>PLoS ONE</i> , 2016, 11, e0160277.	2.5	21
195	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016, 11, e0160761.	2.5	5
196	Blood Myeloid Dendritic Cells and slanDC in Antiretroviral Therapy- Suppressed HIV-Infected Patients. <i>Current HIV Research</i> , 2016, 14, 331-339.	0.5	6
197	Archetype and Rearranged Non-coding Control Regions in Urothelial Bladder Carcinoma of Immunocompetent Individuals. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 499-510.	2.0	5
198	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016, 11, e0156360.	2.5	0

#	ARTICLE	IF	CITATIONS
199	Pseudo-outbreak of <i>Mycobacterium gordonae</i> in a teaching hospital: importance of strictly following decontamination procedures and emerging issues concerning sterilization. <i>New Microbiologica</i> , 2016, 39, 25-34.	0.1	13
200	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Cona Foundation cohort. <i>HIV Medicine</i> , 2015, 16, 412-420.	2.2	4
201	Large Nosocomial Outbreak Associated with a Norwegian Scabies Index Case Undergoing TNF- α Inhibitor Treatment: Management and Control. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1358-1360.	1.8	16
202	Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy. <i>Prenatal Diagnosis</i> , 2015, 35, 1374-1378.	2.3	3
203	Detecting latent tuberculosis in compromised patients. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 275-282.	3.1	13
204	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015, 10, e0124252.	2.5	7
205	Recent Transmission Clustering of HIV-1 CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. <i>PLoS ONE</i> , 2015, 10, e0135325.	2.5	21
206	Multifunctional Analysis of CD4 ⁺ T-Cell Response as Immune-Based Model for Tuberculosis Detection. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	21
207	Therapeutic strategy for pandrug-resistant <i>Klebsiella pneumoniae</i> severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. <i>International Journal of Infectious Diseases</i> , 2015, 33, 132-134.	3.3	37
208	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , 2015, 2, e98-e106.	4.7	249
209	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2935-2941.	3.9	6
210	Atypical presentation of crusted (Norwegian) scabies. <i>Infection</i> , 2015, 43, 623-624.	4.7	9
211	Role of Sonication in the Microbiological Diagnosis of Implant-Associated Infections: Beyond the Orthopedic Prosthesis. <i>Advances in Experimental Medicine and Biology</i> , 2015, 897, 85-102.	1.6	28
212	Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. <i>Hepatology</i> , 2015, 61, 823-833.	7.3	109
213	Undetectable HCV RNA at treatment week 8 results in high sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480.	2.0	9
214	Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19775.	3.0	0
215	Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	3.0	18
216	Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection. <i>International Journal of Molecular Sciences</i> , 2014, 15, 9184-9208.	4.1	80

#	ARTICLE	IF	CITATIONS
217	Taming HIV-Related Inflammation with Physical Activity: A Matter of Timing. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 936-944.	1.1	45
218	Long-term IFN- γ and IL-2 response for detection of latent tuberculosis infection in healthcare workers with discordant immunologic results. <i>Journal of Immunological Methods</i> , 2014, 414, 51-57.	1.4	12
219	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3085-3094.	3.0	6
220	Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant <i>Klebsiella pneumoniae</i> bloodstream infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1718-1720.	3.0	56
221	<i>Legionella pneumophila</i> pneumonia during telaprevir-based triple therapy for HCV chronic hepatitis. <i>Infection</i> , 2014, 42, 225-226.	4.7	2
222	Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 35-40.	1.2	4
223	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 735-741.	3.0	16
224	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1377-1384.	3.0	13
225	Multi-functional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists. <i>Clinical and Experimental Immunology</i> , 2014, 176, 410-417.	2.6	19
226	HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression. <i>Digestive and Liver Disease</i> , 2014, 46, e11.	0.9	2
227	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e109791.	2.5	26
228	Interferon- γ release assay in HIV-infected patients with active tuberculosis: impact of antituberculous drugs on host immune response. <i>New Microbiologica</i> , 2014, 37, 153-61.	0.1	8
229	Extraviral modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc. <i>New Microbiologica</i> , 2014, 37, 225-9.	0.1	3
230	Sonication technique improves microbiological diagnosis in patients treated with antibiotics before surgery for prosthetic joint infections. <i>New Microbiologica</i> , 2014, 37, 321-8.	0.1	35
231	<i>Mycobacterial Interferon-γ Release Variations During Longterm Treatment with Tumor Necrosis Factor Blockers: Lack of Correlation with Clinical Outcome.</i> <i>Journal of Rheumatology</i> , 2013, 40, 157-165.	2.0	30
232	Postpartum fever in the presence of a fibroid: <i>Sphingomonas paucimobilis</i> sepsis associated with pyomyoma. <i>BMC Infectious Diseases</i> , 2013, 13, 574.	2.9	17
233	Late onset invasive pneumococcal disease in a liver transplanted patient: beyond the <sc>A</sc>ustrian syndrome. <i>Transplant Infectious Disease</i> , 2013, 15, E111-4.	1.7	11
234	Interferon- γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis. <i>British Journal of Dermatology</i> , 2013, 169, 1133-1140.	1.5	22

#	ARTICLE	IF	CITATIONS
235	Sonication of Explanted Cardiac Implants Improves Microbial Detection in Cardiac Device Infections. <i>Journal of Clinical Microbiology</i> , 2013, 51, 496-502.	3.9	38
236	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	2.9	68
237	Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy. <i>Archivio Italiano Di Urologia Andrologia</i> , 2013, 85, 157.	0.8	16
238	Hepatitis E Virus Genotype 4 Outbreak, Italy, 2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 110-114.	4.3	90
239	The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. <i>BMC Infectious Diseases</i> , 2013, 13, 473.	2.9	38
240	Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. <i>Isrn Aids</i> , 2013, 2013, 1-6.	2.5	6
241	Study of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) carriage in a population of HIV-negative migrants and HIV-infected patients attending an outpatient clinic in Rome. <i>Annali Di Igiene: Medicina Preventiva E Di Comunita</i> , 2013, 25, 99-107.	0.7	8
242	Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 510-511.	3.0	5
243	<i>Bartonella henselae</i> Infection Presenting With Ocular and Hepatosplenic Manifestations in an Immunocompetent Child. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 882-883.	2.0	2
244	Serial interferon- γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. <i>Clinical Rheumatology</i> , 2012, 31, 1567-1575.	2.2	29
245	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. <i>Cytokine</i> , 2012, 57, 54-60.	3.2	6
246	Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. <i>American Journal of Hematology</i> , 2012, 87, 749-753.	4.1	24
247	Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects. <i>Journal of Infection</i> , 2012, 64, 82-88.	3.3	24
248	Pandemic influenza H1N1, legionellosis, splenic rupture, and vascular thrombosis. <i>Journal of Postgraduate Medicine</i> , 2012, 58, 228-229.	0.4	6
249	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
250	In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection. <i>PLoS ONE</i> , 2011, 6, e28499.	2.5	22
251	HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS. <i>Current HIV Research</i> , 2011, 9, 148-153.	0.5	68
252	<i>In vitro</i> effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. <i>Clinical and Experimental Immunology</i> , 2011, 166, 184-190.	2.6	45

#	ARTICLE	IF	CITATIONS
253	Influence of previous tuberculin skin test on serial IFN- γ release assays. <i>Tuberculosis</i> , 2011, 91, 322-326.	1.9	27
254	Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 70.	0.8	9
255	Adherence and Genotypic Drug Resistance Mutations in HIV-1-Infected Patients Failing Current Antiretroviral Therapy. <i>Journal of Chemotherapy</i> , 2011, 23, 24-27.	1.5	4
256	Severe and Persistent Depletion of Circulating Plasmacytoid Dendritic Cells in Patients with 2009 Pandemic H1N1 Infection. <i>PLoS ONE</i> , 2011, 6, e19872.	2.5	31
257	Current trends in management of hepatitis B virus reactivation in the biologic therapy era. <i>World Journal of Gastroenterology</i> , 2011, 17, 3881.	3.3	51
258	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2011, 34, 109-46.	0.1	20
259	Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, e13-e14.	2.1	10
260	Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. <i>Antiviral Therapy</i> , 2010, 15, 929-932.	1.0	17
261	Diagnostic and therapeutic approach in a rare case of primary bilateral adrenal tuberculosis. <i>Journal of Medical Microbiology</i> , 2010, 59, 1527-1529.	1.8	6
262	Pacemaker Lead Endocarditis Due to Multidrug-Resistant <i>Corynebacterium striatum</i> Detected with Sonication of the Device. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4669-4671.	3.9	34
263	Primary retroperitoneal abscesses due to <i>Rhodococcus equi</i> in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline. <i>International Journal of Infectious Diseases</i> , 2010, 14, e533-e535.	3.3	11
264	The role of HIV-DNA testing in clinical practice. <i>New Microbiologica</i> , 2010, 33, 1-11.	0.1	19
265	Pulmonary embolism and acute cytomegalovirus infection in an immunocompetent patient. <i>Infezioni in Medicina</i> , 2010, 18, 270-2.	1.1	2
266	In Vivo Release of Alpha-Defensins in Plasma, Neutrophils and CD8 T Lymphocytes of Patients with HIV Infection. <i>Current HIV Research</i> , 2009, 7, 650-655.	0.5	13
267	Case 11-2009: A Man with Fever, Headache, Rash, and Vomiting. <i>New England Journal of Medicine</i> , 2009, 361, 312-314.	27.0	3
268	Lack of community-associated MRSA in Rome. <i>Journal of Hospital Infection</i> , 2009, 71, 374-376.	2.9	6
269	Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. <i>Atherosclerosis</i> , 2009, 204, e1-e3.	0.8	11
270	The Absence of HIV Mutations in Cerebrospinal Fluid and in Peripheral Blood Mononuclear Cells During a Regimen Containing Trizivir Plus Tenofovir. <i>Journal of Chemotherapy</i> , 2009, 21, 455-457.	1.5	1

#	ARTICLE	IF	CITATIONS
271	In Vivo and In Vitro Effects of Antituberculosis Treatment on Mycobacterial Interferon- \hat{I}^3 T Cell Response. PLoS ONE, 2009, 4, e5187.	2.5	48
272	Atypical Localization of Leishmaniasis in an Intestinal Polyp. Infection, 2008, 36, 187-188.	4.7	4
273	QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculosis. Diagnostic Microbiology and Infectious Disease, 2008, 62, 395-401.	1.8	6
274	Urolithiasis Under Atazanavir Boosted and Tenofovir Therapy: A Case Report. Journal of Chemotherapy, 2008, 20, 143-144.	1.5	5
275	Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count. Current HIV Research, 2008, 6, 19-27.	0.5	23
276	Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up. HIV Clinical Trials, 2007, 8, 182-188.	2.0	6
277	Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. Aids, 2007, 21, 677-684.	2.2	34
278	Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends in Molecular Medicine, 2007, 13, 449-459.	6.7	71
279	Characterization of circulating blood dendritic cell subsets DC123+ (Lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate, 2007, 67, 1-7.	2.3	37
280	Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nature Medicine, 2007, 13, 1431-1439.	30.7	74
281	Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor- \hat{I}^{\pm} (anti-TNF- \hat{I}^{\pm}) treatment. Clinical Microbiology and Infection, 2007, 13, 1036-1037.	6.0	19
282	Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Tropica, 2006, 99, 83-87.	2.0	16
283	Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response. Clinical and Experimental Immunology, 2006, 143, 329-337.	2.6	50
284	Interleukin-15 enhances the secretion of IFN- \hat{I}^3 and CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunology Letters, 2006, 103, 192-195.	2.5	19
285	Abdominal aortic mycotic aneurysm, psoas abscess, and aorto-bisiliac graft infection due to Salmonella typhimurium. Journal of Infection and Chemotherapy, 2006, 12, 52.	1.7	0
286	HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 781-787.	4.9	20
287	Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. Expert Opinion on Pharmacotherapy, 2006, 7, 2233-2241.	1.8	2
288	Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression. Aids, 2005, 19, 841-842.	2.2	6

#	ARTICLE	IF	CITATIONS
289	Abdominal aortic mycotic aneurysm, psoas abscess, and aorto-bisiliac graft infection due to <i>Salmonella typhimurium</i> . <i>Journal of Infection and Chemotherapy</i> , 2005, 11, 297-299.	1.7	5
290	Rapid identification of <i>Bartonella henselae</i> by real-time polymerase chain reaction in a patient with cat scratch disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 53, 75-77.	1.8	9
291	Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. <i>Clinical and Experimental Immunology</i> , 2004, 135, 280-285.	2.6	9
292	Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. <i>Brain</i> , 2004, 127, 398-407.	7.6	52
293	Interleukin-15 modulates interferon- γ and β -chemokine production in patients with HIV infection: implications for immune-based therapy. <i>Cytokine</i> , 2004, 25, 283-290.	3.2	18
294	Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy?. <i>Trends in Immunology</i> , 2004, 25, 121-125.	6.8	39
295	New Case of Acute Hepatitis Following the Consumption of Shou Wu Pian, a Chinese Herbal Product Derived from <i>Polygonum multiflorum</i> . <i>Annals of Internal Medicine</i> , 2004, 140, W-30.	3.9	74
296	Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. <i>Biochemical Pharmacology</i> , 2003, 66, 1505-1512.	4.4	36
297	Effect of Limonin and Nomilin on HIV-1 Replication on Infected Human Mononuclear Cells. <i>Planta Medica</i> , 2003, 69, 910-913.	1.3	97
298	Matrix Metalloproteinase-9 and Tissue Inhibitors of Matrix Metalloproteinase-1 in Plasma of Patients Co-Infected with HCV and HIV. <i>HIV Clinical Trials</i> , 2002, 3, 310-315.	2.0	27
299	In vitro Anti-HIV Activity of Oleanolic Acid on Infected Human Mononuclear Cells. <i>Planta Medica</i> , 2002, 68, 111-114.	1.3	95
300	Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naïve and -treated patients. <i>Aids</i> , 2002, 16, 181-188.	2.2	56
301	Discordant response to antiretroviral therapy. <i>Aids</i> , 2002, 16, 1877-1885.	2.2	18
302	Circulating Levels of Interleukin-7 in Antiretroviral-Naïve and Highly Active Antiretroviral Therapy-Treated HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2001, 2, 108-112.	2.0	37
303	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. <i>Journal of Pathology</i> , 2001, 193, 200-209.	4.5	47
304	Rhabdomyolysis after cerivastatin/gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. <i>Aids</i> , 2001, 15, 820-821.	2.2	35
305	Relapsing and disseminated VZV infection associated with post-zoster neuralgia in an HIV-infected patient. <i>Journal of Headache and Pain</i> , 2000, 1, 131-132.	6.0	0
306	CASE REPORT: Long-term Remission of Human Immunodeficiency Virus-associated Visceral Leishmaniasis after Initiation of Potent Combination Antiretroviral Treatment: Report of Two Cases. <i>Journal of Infection</i> , 2000, 40, 94-96.	3.3	13

#	ARTICLE	IF	CITATIONS
307	Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. <i>Blood</i> , 2000, 96, 1979-1984.	1.4	42
308	Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. <i>Journal of NeuroVirology</i> , 2000, 6, 156-163.	2.1	75
309	Ex Vivo and In Vitro Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Apoptosis. <i>Journal of Infectious Diseases</i> , 2000, 182, 1536-1539.	4.0	34
310	Changes in Circulating Levels of Soluble Cell Adhesion Molecules Following Highly Active Antiretroviral Treatment of HIV-1-Infected Patients. <i>Clinical Immunology</i> , 2000, 95, 212-217.	3.2	17
311	Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. <i>Blood</i> , 2000, 96, 1979-1984.	1.4	12
312	Reduction of IFN-g and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects. <i>Aids</i> , 1999, 13, 1333-1336.	2.2	13
313	Search for an antibody profile of <i>Rhodococcus equi</i> infection in AIDS patients despite the diversity of isolates and patient immune dysfunction. <i>Microbes and Infection</i> , 1999, 1, 663-670.	1.9	7
314	Reversal of AIDS dementia after combination therapy with stavudine, lamivudine, and zidovudine. <i>Journal of Neurology</i> , 1999, 246, 972-973.	3.6	4
315	Human herpesvirus-8 in lymphomatous and nonlymphomatous body cavity effusions developing in Kaposi's sarcoma and multicentric Castleman's disease. <i>Annals of Diagnostic Pathology</i> , 1999, 3, 357-363.	1.3	29
316	Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. <i>Aids</i> , 1999, 13, 883-890.	2.2	72
317	<i>Rhodococcus equi</i> infection of monocytes/macrophages from human immunodeficiency virus (HIV)-infected patients and healthy individuals: evaluation of intracellular killing and nitric oxide production. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 21, 11-17.	2.7	8
318	Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis. <i>Clinical and Experimental Immunology</i> , 1998, 114, 210-214.	2.6	50
319	Autoimmune T-Cell Response to the CD4 Molecule in HIV-Infected Patients. <i>Viral Immunology</i> , 1998, 11, 9-17.	1.3	17
320	<i>Rhodococcus equi</i> infection of monocytes/macrophages from human immunodeficiency virus (HIV)-infected patients and healthy individuals: evaluation of intracellular killing and nitric oxide production. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 21, 11-17.	2.7	0
321	In vitro production of tumor necrosis factor- α , interleukin-6 and interleukin-8 from normal human peripheral blood mononuclear cells stimulated by <i>Rhodococcus equi</i> . <i>Veterinary Microbiology</i> , 1997, 56, 277-285.	1.9	5
322	Cerebrospinal Fluid Cytokines in Patients with Tuberculous Meningitis. <i>Clinical Immunology and Immunopathology</i> , 1997, 84, 171-176.	2.0	75
323	Central nervous system involvement as a relapse of disseminated histoplasmosis in an Italian AIDS patient. <i>Journal of Infection</i> , 1997, 35, 83-84.	3.3	15
324	Marked activation of the tumour necrosis factor system in AIDS-associated cryptococcosis. <i>Aids</i> , 1996, 10, 1436-1438.	2.2	7

#	ARTICLE	IF	CITATIONS
325	Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects.. Journal of Experimental Medicine, 1996, 183, 2509-2516.	8.5	47
326	Cerebrospinal fluid antiganglioside antibodies in patients with AIDS. Infection, 1995, 23, 288-291.	4.7	7
327	Defective production of interferon- γ and tumour necrosis factor- α by AIDS mononuclear cells after in vitro exposure to Rhodococcus equi. Mediators of Inflammation, 1995, 4, 306-309.	3.0	8
328	Rhodococcus equi Virulence-Associated Antigens and Specific Antibody Response in AIDS Patients Infected with R. equi. Clinical Microbiology and Infection, 1995, 1, 18-23.	6.0	6
329	Tumour Necrosis Factor- α Production and Immune Cell Activation in Tuberculous Meningitis. Mediators of Inflammation, 1994, 3, 57-60.	3.0	3
330	Cytomegalovirus encephalitis in two patients with AIDS receiving ganciclovir for cytomegalovirus retinitis. Journal of Infection, 1994, 29, 331-337.	3.3	12
331	Detection of cytomegalovirus-matrix protein (pp65) in leukocytes of HIV-infected patients with painful peripheral neuropathy. Journal of Medical Virology, 1994, 44, 172-175.	5.0	14
332	Humoral Immune Response to Rhodococcus equi in AIDS Patients with R. equi Pneumonia. Journal of Infectious Diseases, 1994, 169, 1179-1180.	4.0	11
333	Myelin degrading activity in the CSF of HIV-1-infected patients with neurological diseases. NeuroReport, 1994, 6, 157-160.	1.2	17
334	Cranial salmonella abscess with parietal bone osteomyelitis in an HIV-infected patient. Aids, 1992, 6, 749.	2.2	11
335	Cerebrospinal fluid myelin basic protein in AIDS dementia complex. Aids, 1992, 6, 1214.	2.2	3
336	Cerebrospinal fluid myelin basic protein as predictive marker of demyelination in AIDS dementia complex. Journal of Neuroimmunology, 1992, 36, 251-254.	2.3	30
337	Cerebrospinal fluid markers for the monitoring of AIDS dementia complex severity. Aids, 1991, 5, 464.	2.2	13
338	Detection of mycobacterial antigen by dot blot assay in the cerebrospinal fluid of patients with tuberculous meningitis. Journal of Infection, 1991, 22, 106-107.	3.3	11
339	Detection of cerebrospinal fluid antibodies against myelin basic protein in patients with AIDS dementia complex. Molecular and Chemical Neuropathology, 1991, 14, 227-236.	1.0	16
340	Serum β 2-M in asymptomatic HIV-infected patients treated with zidovudine. Aids, 1990, 4, 1297.	2.2	5
341	Humoral and cellular immune responses to salmonella typhi in patients with typhoid fever. Journal of Clinical Laboratory Analysis, 1989, 3, 191-195.	2.1	6
342	Anticardiolipin antibody in the acquired immunodeficiency syndrome: a marker of Pneumocystis carinii infection?. Journal of Infection, 1989, 18, 100-101.	3.3	4

#	ARTICLE	IF	CITATIONS
343	Use of dot immunobinding assay (DIB) for the rapid diagnosis of human brucellosis. <i>Journal of Infection</i> , 1987, 14, 88-89.	3.3	7
344	Human Amoebiasis: The Interaction of Lymphocyte Surface-Bound Immune Complexes and Pmns Impairs T Cell Proliferative Responses to <i>E. Histolytica</i> Mitogen. <i>Immunological Investigations</i> , 1985, 14, 131-144.	2.0	2